Document |
Document Title |
JP2022137128A |
To provide small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on...
|
JP2022538907A |
The present disclosure is directed to chemical compounds and the use of such compounds in the treatment of diseases associated with adrenergic receptors.
|
JP2022538773A |
The present invention provides polymeric support compounds of Formula I or III comprising a polymeric support linked by conjugation to one or more aminobenzazepine derivatives. The present invention also provides an aminobenzazepine deri...
|
JP2022125073A |
To obtain a specific crystal form from a solution obtained by dissolving a compound in a solvent.A purification method for crystallizing a compound having at least one crystal form includes setting a specific infrared wavelength precipit...
|
JP7125674B2 |
The present invention is a method of producing ε-caprolactam through adipamide as an intermediate, and characteristically includes a lactamization step of reacting adipamide, formed from a material compound, with hydrogen and ammonia in...
|
JP2022537158A |
The present application relates to immunoconjugates of formula (I) comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The present application also provides an aminobenzazepine derivative intermediat...
|
JP7099672B2 |
Novel tetrahydroisoquinoline and tetrahydrobenzazepine compounds of formula (I) capable of modulating the G-protein-coupled receptor GPR120, compositions comprising the compounds, and methods for their use for controlling insulin levels ...
|
JP7096958B2 |
A refining method according to the present invention is a refining method for crystallizing a compound with at least one crystal form, including setting, as a target wavelength and a target temperature, a specific infrared wavelength and...
|
JP7096956B2 |
A refining method according to the present invention is a refining method for crystallizing a compound with at least one crystal form, including setting, as a target wavelength and a target temperature, a specific infrared wavelength and...
|
JP7088933B2 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
|
JP2022090290A |
To provide a light source device for photochemical reaction having a heat sink made of an aluminum alloy resistant to corrosion, a photochemical reaction device and method using the light source device, and a method for producing lactam ...
|
JP2022527731A |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof. The compounds, compositions, methods and kits of the present invention are useful in the treatment of pain, itch and neurological inf...
|
JP7064512B2 |
The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
|
JP2022064180A |
To provide a heterocyclic compound with orexin type 2 receptor agonist activity.A compound represented by formula (I), where each symbol is as described in the specification, or a salt thereof has orexin type 2 receptor agonist activity ...
|
JP7055160B2 |
The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, for use in the treatment, prevention, and/or diagnosis of a disease selected from the group consistin...
|
JP2022055368A |
To provide a novel production method capable of efficiently producing an optically active N-[(S)-1-hydroxypropane-2-yl]-4-methyl-1-[2-methyl-4-(3-meth
yl-1H-pyrazole-1-yl)benzoyl]-2,3,4,5-tetrahydro-1H-benzo[b]a
zepine-4-carboxamide.Ther...
|
JP2022518599A |
The present invention relates to a quaternary ammonium salt compound and a method and use thereof, and belongs to the field of chemical medicine. The present invention provides a compound represented by Formula I, or a pharmaceutically a...
|
JP2022041072A |
To provide an inhibitor effective against IMP type metallo-β-lactamase.The present invention discloses a compound represented by the following formula [R1 and R4 each denote an optionally substituted, C1-10 alkyl group, C2-10 alkenyl gr...
|
JP2022515609A |
The present invention relates to a new process for producing epsilon caprolactam (CPL) from 6-aminocaproic acid (6-ACA), which can be obtained from conventional petrochemical processes or from biochemical processes. The process of the pr...
|
JP7022702B2 |
This invention relates to new benzazepine dicarboxamide compounds of the formula (I) wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agon...
|
JP2022513051A |
The present invention relates to NMDA (N-methyl-D-aspartic acid) receptor-related diseases or disorders by positron emission tomography (PET), single photon emission tomography (SPECT), liquid scintillation and / or autoradiography-based...
|
JP7004641B2 |
The invention relates to the use of thermoplastic molding masses to produce molded bodies of any type having improved optical properties, said molding masses containing A) 30 to 99.99 wt% of a thermoplastic polyamide, B) 0.01 to 10 wt% o...
|
JP2022007984A |
To provide a novel agricultural chemical, in particular a herbicide.The present invention discloses a ketone or oxime compound represented by formula (1): [where B is B-1, B-2 or B-3, Q is an oxygen atom, NOR7 or the like, R6 is a hydrog...
|
JP6971249B2 |
An acyclic fluorinated compound of formula (I) is amine -containing acyclic hydrofluoroethers. The acyclic fluorinated compound is useful as heat transfer, solvent cleaning, fire extinguishing agents and electrolyte solvents and additives.
|
JP2021176821A |
To provide a new carotenoid derivative excellent in hydrophilic property and oral absorption.A carotenoid derivative in formula (1) is provided. (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are the s...
|
JP2021172624A |
To provide new means that uses trialkyl phosphate and a strong base reaction agent to cause an alkylation reaction with various substrates such as carboxylic acid, ketone, aldehyde, amine, amide, thiol, ester or Grignard reagent with hig...
|
JPWO2020050160A1 |
A catalyst for hydrogenation reaction of an amide compound, which is a catalyst in which platinum and vanadium are supported on hydroxyapatite and whose platinum surface is covered with vanadium by 15 to 80%, is an amine compound contain...
|
JP2021138751A |
To provide methods of treating CFTR-mediated diseases, such as cystic fibrosis.The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions, treatment methods and k...
|
JP2021130637A |
To provide a method for inhibiting dirt caused by evaporation of cyclohexanone oxime in gas phase method caprolactam production equipment.There is provided a method for inhibiting dirt in a production process of ε-caprolactam comprising...
|
JP2021132174A |
To provide a method for operating a light irradiation device, capable of solving problems associated with the discoloration of an encapsulant for a light emitting diode, specifically suitable for use in a photoreaction.There is provided ...
|
JP6917226B2 |
To provide a method for purifying 1-(4-amino-2-methylbenzoyl)-7-chloro-5-oxo-2,3,4,5-tetrahydr
o-1H-1-benzazepine, which is one of the producing intermediates of tolvaptan.This invention relates to a purification method, comprising the s...
|
JP6915056B2 |
A method for predicting a therapeutic effect of a chemotherapy using an antitumor agent comprising an LSD1 inhibitor in a cancer patient based on an expression level of INSM1 in a sample containing tumor cells isolated from the cancer pa...
|
JP2021098720A |
To provide a method for preparing ε-caprolactam (caprolactam) from biochemically prepared 6-aminocaproic acid (6-ACA).A method for preparing caprolactam comprises recovering a mixture containing 6-aminocaproic acid from a culture medium...
|
JP6893501B2 |
This invention relates to novel sulfinylphenyl or sulfonimidoylphenyl benzazepine compounds of the formula (I) wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts there...
|
JP6872443B2 |
To provide improved methods of producing 7-chloro-1-(2-methyl-4-nitrobenzoyl)-5-oxo-2,3,4,5-tetrahydr
o-1H-1-benzazepine.The present invention provides methods of producing 7-chloro-1-[2-methyl-4-[(2-methylbenzoyl)amino]benzoyl]-5-ox
o-2...
|
JP6866894B2 |
A production method of ε-caprolactam, comprising a step of Beckmann-rearranging cyclohexanone oxime in a gas phase in the presence of a zeolite catalyst containing a silicon element and at least one element selected from the group consi...
|
JP6852181B2 |
The present invention relates to a process for purifying caprolactam from solutions of crude caprolactam by a direct treatment with one or more alkaline compounds of polyvalent metals, preferably bivalent and trivalent, without resorting...
|
JP6843979B2 |
The present invention provides a compound represented by Formula (I) or a salt thereof; an LSD1 inhibitor that contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition that contains the compound or a ...
|
JP2021504314A |
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof and methods of using them.
|
JP2021014406A |
To provide a compound that is highly water-soluble and has a vasopressin V2 receptor antagonistic action, which is particularly suitable for parenteral injections, and to provide a pharmaceutical containing said compound.Provided are a c...
|
JP6820254B2 |
and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a...
|
JP2021500416A |
The present invention provides a large affinity and activity for the voltage-gated calcium channel (VGCC) subunit α2δ, or a dual activity for the voltage-gated calcium channel (VGCC) subunit α2δ and the noradrenaline transporter (NET...
|
JP6804540B2 |
The present invention discloses a compound shown in formula I or a stereoisomer, pharmaceutically acceptable salt, crystal form, solvate or isotopologue thereof. The compound of the present invention shows excellent inhibition activity a...
|
JP6790040B2 |
The present invention relates to a list of specific 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}etha
n-1-one derivatives and related compounds as fatty acid synthase (FAS or FASN) inhibitors for treating cancer and pharmacuti...
|
JP6789578B2 |
Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing fo...
|
JP6786052B2 |
A method of producing µ-caprolactam from 3-oxoadipic acid which is preferred as a biomass resource is disclosed. The method of producing µ-caprolactam includes: the step 1 of mixing at least one selected from the group consisting of 3-...
|
JP6754778B2 |
The present invention relates to compounds according to Formula I : or a pharmaceutically acceptable salt thereof wherein the variables have the meanings defined in the claims. The compounds can be used as inhibitors of ROR³ and are use...
|
JP2020114227A |
To provide compositions of industrially useful alcohol, amine, lactone, lactam and acid, linear fatty acid and linear fatty alcohol with the carbon length of 7 to 25, linear alkane and linear α-alkene with the carbon length of 6 to 24, ...
|
JP6728208B2 |
wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as...
|
JP2020519647A |
The present invention provides a novel heterocyclic compound of the general formula (I) including a novel compound of the formula (Ia), and a pharmaceutical composition containing them. In addition, for use in the treatment and / or prev...
|